1 / 22

ESC Congress 2008 Clinical Trial Summary

ESC Congress 2008 Clinical Trial Summary. 3T/2R. Troponin I or T >3x ULN at 48 hours: 20% for tirofiban vs. 35% for placebo (p = 0.009) MACE at 30 days: 21% vs. 37% (0.006), respectively TIMI major bleeding at 30 days: 0 vs. 0.

hcorrales
Download Presentation

ESC Congress 2008 Clinical Trial Summary

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ESC Congress 2008 Clinical Trial Summary

  2. 3T/2R Troponin I or T >3x ULN at 48 hours: 20% for tirofiban vs. 35% for placebo (p = 0.009) MACE at 30 days: 21% vs. 37% (0.006), respectively TIMI major bleeding at 30 days: 0 vs. 0 Trial design:Patients undergoing PCI were screened for poor response to aspirin and/or clopidogrel. Poor responders were then randomized to tirofiban (n = 132) or placebo (n = 131). Follow-up was 30 days. Results (p = 0.009) (p = 0.006) 37 35 % 20 21 Conclusions • Tirofiban is beneficial at reducing MI within 48 hours after PCI among poor responders to aspirin and/or clopidogrel • Tirofiban also reduced MACE at 30 days • There were no major bleeds in either group Troponin I or T >3x ULN at 48 hours MACE at 30 days Tirofiban Placebo Presented by Dr. Marco Valgimigli at ESC 2008

  3. APPRAISE-1 ISTH major or CRNM bleeding: 7.9% for 10 mg apixaban, 5.7% for 5 mg apixaban, 3% for placebo (p = 0.005 for high-dose vs. placebo and p = 0.09 for low-dose vs. placebo) Death, MI, recurrent ischemia, or stroke: 6.0%, 7.6%, 8.7% (p = 0.07 for high-dose vs. placebo and p = 0.21 for low-dose vs. placebo), respectively Trial design:Patients recovering from an ACS were randomized to apixaban 10 mg daily (n = 318), apixaban 2.5 mg twice daily (n = 317), or placebo (n = 611). Study medications were administered for 6 months. Results p = 0.005 for high-dose vs. placebo p = 0.09 for low-dose vs. placebo 7.9 5.7 % Conclusions 3 • This dose-finding study reveals that bleeding is increased among patients with a recent ACS with higher doses of apixaban compared with placebo • Although this study was not powered for efficacy, adverse events appeared to be lowest with 10 mg apixaban ISTH major or clinically relevant nonmajor bleeding Apixaban 5 mg Apixaban 10 mg Placebo Presented by Dr. John Alexander at ESC 2008

  4. ATHENA Dronedarone associated with a 24% ↓ in cardiac hospitalizations or death vs. placebo (p < 0.001) Overall mortality similar (p = 0.17); cardiovascular mortality lower with dronedarone (p = 0.03) Higher GI side effects and increased creatinine with dronedarone; other side effects similar (p = 0.17) Trial design: High-risk patients with paroxysmal or persistent atrial fibrillation or flutter were randomized to dronedarone 400 mg twice daily or placebo. Patients were followed for a mean of 21 months. Results 10 6.0 5.0 % 5 Conclusions • Dronedarone is safe and effective in the chronic management of atrial fibrillation in high-risk patients • Head-to-head comparison with amiodarone is awaited 0 Mortality Dronedarone (n = 2,301) Placebo (n = 2,327) Presented by Dr. Stefan Hohnloser at Heart Rhythm 2008

  5. BEAUTIFUL Difference in heart rate at 24 months: 5.6 bpm lower with ivabradine CV death, MI, or HF: 15.4% for ivabradine vs. 15.3% for placebo (p = 0.94) All-cause mortality:10.4% vs.10.1% (p=0.55) HF admission: 7.8% vs. 7.9% (p = 0.85) Trial design:Patients with stable CAD and moderate LV dysfunction were randomized to the sinoatrial node inhibitor, ivabradine (n = 5,479), or placebo (n = 5,438). Median follow-up was 19 months. Results (p = 0.94) (p = 0.55) 15.4 15.3 10.4 10.1 % Conclusions • Ivabradine produces a sustained reduction in heart rate over long-term follow-up • Among patients with stable coronary disease and moderate LV dysfunction, ivabradine does not improve mortality, MI, or HF admissions CV death, MI, HF admission All-cause mortality Ivabradine Placebo Fox K, et al. Lancet 2008;Aug 31:[Epub before print]

  6. CARDia Primary endpoint (death, MI, stroke) was similar between CABG and PCI (10.2% vs. 11.6%, p = 0.63) Significant ↓ in repeat revascularization in CABG arm (2% vs. 9.9%, p = 0.001). True in drug-eluting stent subset also Trend toward increased CVA in CABG arm (p = 0.09) (p = 0.63) (p = 0.001) CABG (n = 254) PCI (n = 256) Trial design: Diabetic patients with multi-vessel disease or complex single-vessel disease, but not left main disease, were randomized to either CABG or PCI. Clinical outcomes were compared at 12 months. Results 20 20 15 15 11.6 % % Conclusions 10.2 9.9 10 10 • Similar incidence of death, MI, or stroke in diabetics with CABG or PCI • CABG was associated with fewer repeat revascularizations compared with PCI • No difference in death, MI, but trend toward increased stroke with CABG, as suggested by other studies 5 5 2.0 0 0 Repeat revascularization Primary endpoint Presented by Dr. Akhil Kapur at ESC 2008

  7. CARESS-in-AMI 86% of the immediate PCI group underwent PCI vs. 30% of the standard care group Death, MI, or refractory ischemia at 30 days (4.4% vs. 10.7%, p = 0.005) Refractory ischemia (0.3% vs. 4.0%, p = 0.003) Trial design:STEMI patients admitted to non-PCI hospitals and initially treated with heparin, half-dose reteplase, and abciximab were randomized to immediate transfer for urgent PCI (n = 299) or standard therapy with rescue PCI if needed (n = 301). Results (p = 0.005) (p = 0.47) 10.7 % 4.4 3.4 Conclusions 2.3 • STEMI patients treated with half-dose lytics and abciximab did better with immediate transfer for PCI • This approach reduced death, MI, or refractory ischemia at 30 days • Benefit driven by reduction in refractory ischemia MACE Major bleeding Transfer for PCI (n = 299) Standard therapy (n = 301) Di Mario C, et al. Lancet 2008;371:559-68

  8. DECREASE III Myocardial ischemia was significantly reduced with statin (OR 0.53; 95% CI 0.32-0.88, p = 0.016) LDL (p < 0.001) and hs-CRP (p  0.001) were lower in statin arm Incidence of adverse events was similar (p = 0.016) (p = 0.039) Fluvastatin XL (n = 250) Placebo (n = 247) Trial design: Patients undergoing noncardiac vascular surgery were randomized to fluvastatin XL or placebo, in addition to beta-blockers. Clinical outcomes were compared at 1 month. Results 19.0 20 20 15 15 Conclusions 10.9 % % 10.1 10 10 • Perioperative statin therapy was associated with improved outcomes in high-risk patients undergoing noncardiac vascular surgery • Results add to current literature on the benefit of statins in the perioperative period 4.8 5 5 0 0 Myocardial ischemia CV death or MI Presented by Dr. Don Poldermans at ESC 2008

  9. FIRE Total late enhancement zone at 5 days: 21.7 g for FX06 vs. 27.3 g for placebo (p = 0.21) and at 4 months: 15.4 g vs. 19.3 g (p = 0.36), respectively LVEF at 4 months: 49% vs. 49%, respectively Serious adverse events: 18% vs. 24%, respectively Trial design:STEMI patients were randomized to the fibrin-derived peptide FX04 400 mg intravenously (n = 114) versus placebo (n = 120). Results (p = 0.36) 19.3 15.4 (g) Conclusions Total late enhancement zone at 4 months • This study failed to meet its endpoint of a reduction in total late enhancement • There was no difference in LVEF at follow-up • There were no important safety signals with the use of this agent FX04 Placebo Presented by Dr. Dan Atar at ESC 2008

  10. GISSI-HF: n-3 PUFA Study No difference between the two arms for primary endpoint (death), but significant difference noted on multivariate analysis (HR 0.91, 95.5% CI 0.83-1.0; p = 0.041) No difference in the incidence of first admission for heart failure, but fewer admissions for arrhythmia related issues (p = 0.013) (p = 0.12) (p = 0.013) n-3 PUFA (n = 3,494) Placebo (n = 3,481) Trial design: Patients with symptomatic CHF were randomized to 1 g n-3 PUFA daily or placebo, in addition to optimal medical treatment. Clinical outcomes were compared at 12 months. Results 29.1 30 20 27.3 15 20 % % Conclusions 10 • No significant difference in mortality in the n-3 PUFA arm, compared with placebo in patients with symptomatic heart failure, on optimal treatment • However, multivariate analysis showed n-3 PUFA was associated with small reduction in mortality (absolute RR 1.8%) compared with placebo • Exact mechanism is unclear, although reduction in readmission for arrhythmias was noted 10 4.0 5 3.0 0 0 Arrhythmia related hospitalization Mortality GISSI-HF Investigators. Lancet 2008;Aug 31:[Epub]

  11. GISSI-HF: Rosuvastatin Study All-cause mortality: 29% with rosuvastatin vs. 28% with placebo (p = 0.94) Death or hospital admission for cardiovascular reasons: 57% vs. 56% (p = 0.90), respectively Sudden cardiac death: 9.6% vs. 8.6% (p = 0.26), respectively Trial design:Patients with chronic symptomatic HF were randomized to rosuvastatin 10 mg daily (n = 2,285) or placebo (n = 2,289). Median follow-up, 3.9 years. Results (p = 0.94) (p = 0.90) 57 56 % 29 28 Conclusions All-cause mortality Death or hospital admission for CV reasons • Rosuvastatin 10 mg daily is not beneficial at reducing cardiac outcomes among patients with chronic symptomatic HF • This study should not temper enthusiasm for statins in indicated situations like ACS Rosuvastatin Placebo GISSI-HF Investigators. Lancet 2008;Aug 31:[Epub]

  12. IBIS-2 Lp-PLA2 reduced 59% by darapladib (p < 0.001) Plaque deformability: similar between the groups at follow-up (p = 0.22) Necrotic core volume: -0.5 mm3 with darapladib (p = 0.71); +4.5 mm3 with placebo (p = 0.009) MACE: 17% vs. 19% (p = ns), respectively Trial design:Patients with CAD were randomized to darapladib 160 mg daily (n = 175) vs. placebo (n = 155). Patients underwent IVUS of a nonintervened segment at baseline and at 12 months. Results p = 0.71, change with darapladib p = 0.009, change with placebo 4.5 mm3 Conclusions -0.5 • Treatment with the Lp-PLA2 inhibitor darapladib does not affect plaque deformability • Darapladib appears to stabilize the necrotic lipid core • Similar adverse events between the groups Change in necrotic core volume at follow-up Darapladib Placebo Serruys PW, et al. Circulation 2008;Sep 1:[Epub]

  13. LEADERS Successful stent implantation: 97.5% for biolimus vs. 95.7% for sirolimus (p = 0.05) Death, MI, or TVR: 9.2% vs. 10.5% (p = 0.003 for non-inferiority), respectively Stent thrombosis: 1.9% vs. 2.0% (p = 0.84), respectively Trial design:Patients with stable coronary disease or ACS were randomized to the biolimus-eluting stent with a biodegradable polymer (n = 857) or the sirolimus-eluting stent with a durable polymer (n = 850). Follow-up was for 9 months. Results (p = 0.003 for non-inferiority) (p = 0.84) 10.5 9.2 % Conclusions 2.0 1.9 • Biolimus-eluting stent is non-inferior to sirolimus-eluting stent for death, MI, or TVR • Higher rate of successful implantation with the biolimus-eluting stent • Theoretically, a biodegradable polymer could decrease late stent thrombosis; however, longer-term follow-up is needed Stent thrombosis Death, MI, urgent revascularization Biolimus-eluting stent Sirolimus-eluting stent Windecker S, et al. Lancet 2008;Sept 1:[Epub before print].

  14. PIHRATE ST-resolution at 60 minutes: 50% with thrombectomy vs. 41% with primary PCI (p = 0.28) Myocardial blush grade of 3: 76% vs. 59% (p = 0.023), respectively 6-month mortality: 4.0% vs. 3.1% (p = 0.74), respectively Trial design:Patients with STEMI were randomized to aspiration thrombectomy plus PCI (n = 102) versus primary PCI alone (n = 94). Follow-up was 6 months. Results (p = 0.28) (p = 0.74) 50 4.0 41 % % 3.1 Conclusions ST-segment resolution at 60 minutes 6-month mortality • Among STEMI patients, a strategy of aspiration thrombectomy compared with primary PCI failed to improve ST-resolution after PCI, although it did enhance myocardial blush grade of 3 • Mortality was similar between the groups Aspiration thrombectomy Primary PCI Presented by Dr. Dariusz Dudek at ESC 2008

  15. REGENT EF change: +3% selected cells (p = 0.04), +3% unselected cells (p = 0.01), 0% control (p = 0.73) (p = ns between groups) Death: 1.3%, vs. 1.3%, vs. 2.5% (p = 0.92), respectively Myocardial infarction: 5.0%, vs. 1.3%, vs. 5.0% (p = 0.61), respectively Trial design:Patients with acute MI and LV dysfunction (EF ≤40%) were randomized to selected CD34+ CXCR4+ bone marrow cells (n = 80), unselected bone marrow cells (n = 80), or control (n = 40). Follow-up was 6 months. Results p = ns for stem cell LVEF change compared with control 3 3 20 35 37 21 % 0 Conclusions • In patients with acute MI and LV dysfunction, both selected and unselected bone marrow derived stem cells minimally increased LVEF at 6 months • This did not translate into a difference in LVEF at follow-up between the groups • Similar adverse events between the groups Change in LVEF at 6 months Unselected stem cells Selected stem cells Control Presented by Dr. Michal Tendera at ESC 2008

  16. REVERSE Patients worsened: 16% with CRT vs. 21% with optimal medical therapy (p = 0.1) LV end-systolic volume index: decreased 18.4 ml/m2 vs. 1.3 ml/m2 (p < 0.0001), respectively Risk of heart failure hospitalization reduced with CRT (p = 0.03) Trial design:Patients with LV dysfunction (NYHA class I-II) and wide QRS were randomized to cardiac resynchronization therapy (CRT) (n = 419) or optimal medical therapy (n = 191). Results (p = 0.1) 16 21 % Conclusions • CRT for mild heart failure does not reduce the percentage of patients that clinically worsen • CRT improves LV end-systolic volume index and reduces the risk of hospitalization compared with optimal medical therapy Percentage worsened Medical therapy CRT Presented Dr. Cecilia Linde at SCAI-ACC i2 Summit/ACC 2008

  17. 61% ↓ in LDL in ezetimibe/simvastatin arm No difference in the composite endpoint between the two groups (HR 0.96, 95% CI 0.83-1.12) Increased incidence of cancer (9.9% vs. 7.0%, p = 0.03) and cancer deaths (4.1% vs. 2.5%, p = 0.05) with ezetimibe/simvastatin SEAS (p = NS) (p = 0.05) Ezetimibe/ Simvastatin (n = 943) Placebo (n = 930) Trial design:Patients with asymptomatic mild to moderate calcific AS were randomized to treatment with ezetimibe/simvastatin 10/40 mg or placebo. Cardiovascular outcomes over 4 years were compared. Results 5 38.2 40 35.3 4.1 4 30 3 2.5 % % 20 Conclusions 2 • No benefit with ezetimibe/simvastatin in asymptomatic AS patients other than a reduction in atherosclerotic events • Final full publication is awaited 10 1 0 0 Composite endpoint Deaths from cancer Pedersen TR. Press release July 21, 2008

  18. SYNTAX MACCE was significantly lower in CABG arm compared with PCI (12.1% vs. 17.8%, p = 0.0015), especially for diabetics (p = 0.0025) Significant ↓ in the need for repeat revascularization in CABG arm (p = 0.0001) Death and MI were similar; CVA ↑ with CABG (p = 0.003) (p = 0.0015) (p = 0.0001) CABG (n = 897) DES-PCI (n = 903) Trial design:Patients with severe three-vessel disease or left main (LM) disease were randomized to either CABG or DES-PCI with paclitaxel-eluting stents. Clinical outcomes were compared at 12 months. Results 20 20 17.8 13.7 15 15 12.1 % % Conclusions 10 10 5.9 • CABG was associated with fewer repeat revascularizations compared with DES-PCI in patients with LM or three-vessel disease, but a higher rate of stroke • No difference in death, MI, or thrombosis • Diabetics are especially more likely to benefit with CABG compared with DES-PCI 5 5 0 0 MACCE Repeat revascularization Presented by Dr. Patrick Serruys at ESC 2008

  19. Main reason for PCI only: inoperable (comorbidities); main reason for CABG only: complex anatomy PCI outcomes: MACCE (20.4%), mortality (7.3%), MI (4.2%), repeat revascularization (12%), CVA (0) CABG outcomes: MACCE (8.8%), mortality (2.5%), MI (2.5%), repeat revascularization (3%), CVA (2.2%) SYNTAX Registry Trial design:Patients with severe three-vessel or left main (LM) disease who did not meet criteria for entry into the SYNTAX trial were followed for 12 months in the SYNTAX CABG and PCI registry. Results 25 25 20 20.4 20 20 15 % % 15 Conclusions 12.0 8.8 10 10 10 • The SYNTAX registry describes outcomes in PCI and CABG in patients not eligible for the SYNTAX trial • Of all-comers with three-vessel and/or LM disease, 6.4% were considered inoperable; 35% not feasible for PCI 5 3.0 5 0 0 CABG (n = 1,077) DES-PCI (n = 198) Repeat revascularization MACCE Presented by Dr. Friedrich Mohr at ESC 2008

  20. No difference in final NT-BNP between the 2 arms No difference in the survival (p = 0.06) or hospitalization-free survival (p = 0.46), but ↓ in CHF hospitalization-free survival (p = 0.008) Greater reductions in patients younger than 75 years Quality of life better in older patients with standard therapy TIME-CHF (p < 0.05) Trial design:Patients with chronic systolic HF were randomized to intensified BNP-guided therapy or standard therapy, with the specific inclusion of patients ≥75 years. Clinical outcomes were compared at 18 months. Results 20 15 10 % 6.0 5 Conclusions 2.0 • Intensified BNP-guided therapy was not associated with better survival • Elderly patients do better with standard therapy, including in quality-of-life assessment 0 Change in quality of life, Age ≥75 years Standard therapy (n = 248) Intensified therapy (n = 251) Presented by Dr. H.P. Brunner-La Roccaat ESC 2008

  21. TIMIC Majority in immunosuppressive therapy arm showed an ↑ in LVEF (26.4-48.0%) and ↓ in LV end-diastolic diameter (LVEDD) (68.6-52.8 mm) None of the patients in the placebo arm improved; some showed further ↓ in LVEF and ↑ in LVEDD (p < 0.05) Trial design: Patients with virus-negative inflammatory cardiomyopathy were randomized to either immunosuppressive therapy with prednisone and azathioprine or placebo for 6 months. Echocardiographic parameters were compared at 6 months. Results 30 21.6 15 Conclusions • Immunosuppressive therapy in virus-negative inflammatory cardiomyopathy may be associated with an improvement in LVEF and LVEDD, compared with placebo • Clinical outcomes are awaited • May represent novel approach to heart failure management in these patients % 0 -8.1 -15 Change in LVEF from baseline Immunosuppressive therapy (n = 43) Placebo (n = 42) Presented by Dr. Andrea Frustaci at ESC 2008

  22. TRANSCEND No difference between telmisartan (15.7%) and placebo (17.0%) in the incidence of the primary outcome (CV death, MI, stroke, CHF) (p = 0.22) Stroke, death, or MI was reduced with telmisartan (p = 0.05) No difference in mortality (p = 0.49); marginal reduction in MI (3.9% vs. 5.0%, p = 0.06) (p = 0.22) (p = 0.49) Trial design:Patients at high risk for cardiovascular events, and with intolerance to ACE inhibitors, were randomized to telmisartan or placebo. Patients were followed for a median of 56 months. Results 15 20 17.0 12.3 15.7 11.7 % 10 10 % 5 Conclusions • Telmisartan is not more effective than placebo in reducing the incidence of the composite primary endpoint, but does reduce the incidence of stroke, death, or MI • May be an alternative in high-risk patients, who are intolerant to ACE inhibitors 0 0 Primary endpoint Mortality Telmisartan (n = 2,954) Placebo (n = 2,972) TRANSCEND Investigators. Lancet 2008;Aug 31:[Epub]

More Related